While these results showed a trend towards improved outcomes, they appeared less robust than the confirmed survival benefits of the nivolumab plus chemotherapy arm in the same trial.
← all excerpts
The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review.
1
—
—